

Market Round-up

V24 – 9th November, 2018

General Market News:

- Irish drug wholesale company **Uniphar** has acquired **Bradley Pharmacy Group** in a move that will bring it closer to an initial public offering.
[LINK](#)
- The **FDA** has issued a Class I recall, its most serious and highest recall alert, for strips sold by **Roche Diagnostics** that are used to check warfarin levels.
[LINK](#)
- **FLX Bio** announces clinical trial collaboration agreement with **MSD** for ongoing Phase 1/2 study of FLX475 & Keytruda.
[LINK](#)
- **Merck** launches BioContinuum™ platform for next-generation process improvements
[LINK](#)
- **Takeda** CEO confident of investor backing for \$62 billion **Shire** deal
[LINK](#)
- **GSK** selects **Hitachi** to make T-cell therapy
[LINK](#)
- **Astellas** invests \$256m in Japanese and US antibody and cell therapy sites
[LINK](#)
- **Amgen** picks **Provention** to continue development of **celiac disease** drug
[LINK](#)
- **Novartis** says \$4m price is reasonable for **SMA gene therapy**
[LINK](#)
- **GlaxoSmithKline** to ramp up shingles vaccine production as supply shortage continues
[LINK](#)
- **NICE** says no to expanding use of **AstraZeneca's Lynparza**
[LINK](#)
- **Hikma Pharmaceuticals** and **Vectura** have signed a deal to develop and market generic versions of **GlaxoSmithKline's Ellipta** portfolio
[LINK](#)

NCPE Drug Updates

- A Full Pharmacoeconomic Assessment is recommended for **Jazz Pharmaceuticals's Liposomal daunorubicin and cytarabine**
[LINK](#)

Biologics / Biosimilars:

- **Novartis** backs away from U.S. marketing application for **Rituxan** biosimilar
[LINK](#)
- Amgen files cross-appeal in ongoing battle over Epoetin Alfa
[LINK](#)

Drug Approvals:

- **Pfizer's** new lung cancer treatment **Lorbrena** has received FDA approval for previously treated patients with a specific gene mutation and metastatic disease.
[LINK](#)
- The FDA has granted approval to **Pfizer's** next generation ALK inhibitor lung cancer treatment **Lorbrena**
[LINK](#)
- **Jazz Pharmaceuticals'** chemotherapy **Vyxeos** has won the backing of NICE for routine use on the NHS in England and Wales to treat certain acute myeloid leukaemias (AML).
[LINK](#)

•

Brexit:

- Downing Street has announced the creation of five new business councils, including one to be co-chaired by **GSK's** chief executive **Emma Walmsley**
[LINK](#)
- What are EU countries doing to prepare for a no-deal Brexit?
[LINK](#)

•

Further Reading:

- Bruised, battered, but unbowed. Tony O'Brien's interview with *Susan Mitchell*, *Sunday Business Post*
[LINK](#)
- Simon Harris "at war" with officials as 'worst ever' trolley crisis looms – *Irish Independent article*
[LINK](#)
- How **Amgen** uses **AI** to improve manufacturing deviation investigations
[LINK](#)
